Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$437.49 8.90 (2.08%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 113.76(B)
Last Volume: 1,059,413 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 18 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-24 4 D $217.57 $640,961 D/D (2,946) 43,719     -
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-24 4 D $217.57 $187,980 D/D (864) 15,964     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-24 4 D $217.57 $525,649 D/D (2,416) 36,617     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2021-02-24 4 D $217.57 $119,011 D/D (547) 35,226     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-24 4 D $217.57 $525,649 D/D (2,416) 33,865     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2021-02-24 4 D $217.57 $225,403 D/D (1,036) 31,432     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-18 4 AS $210.08 $1,657,556 D/D (7,825) 36,281 -6%     
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-18 4 AS $210.00 $1,962,366 D/D (9,264) 46,665 -6%     
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-18 4 AS $210.05 $909,828 D/D (4,295) 16,828 -6%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-18 4 AS $210.11 $1,657,590 D/D (7,825) 39,033 -6%     
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-18 4 AS $210.05 $1,657,481 D/D (7,825) 47,635 -6%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2021-02-17 4 D $211.75 $2,958,148 D/D (13,970) 49,676     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-17 4 D $211.75 $1,321,320 D/D (6,240) 44,106     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-17 4 D $211.75 $1,612,053 D/D (7,613) 55,929     -
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-17 4 D $211.75 $580,195 D/D (2,740) 21,123     -
   Kewalramani Reshma CEO & President   •       •      –    2021-02-17 4 D $211.75 $440,440 D/D (2,080) 66,541     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2021-02-17 4 D $211.75 $423,500 D/D (2,000) 32,468     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-17 4 D $211.75 $1,321,320 D/D (6,240) 46,858     -
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-17 4 D $211.75 $1,321,320 D/D (6,240) 55,460     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-02-11 4 AS $210.44 $355,012 D/D (1,686) 38,864 -11%     
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-11 4 AS $210.39 $1,085,593 D/D (5,156) 61,700 -11%     
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-11 4 AS $210.43 $939,068 D/D (4,460) 63,542 -11%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-11 4 AS $210.42 $1,112,274 D/D (5,283) 53,098 -11%     
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-11 4 AS $210.43 $909,179 D/D (4,318) 50,346 -11%     
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-11 4 AS $210.45 $315,437 D/D (1,498) 23,863 -11%     
  3266 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us